Baker Bros. Advisors’s Autolus Therapeutics AUTL Stock Holding History

Baker Bros. Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-461,726	Closed	-$2.65M	–	121
2021 Q1	$2.65M	Sell	461,726 -320,457	-41%	-$2.37M	0.01%	111
2020 Q4	$6.99M	Buy	782,183 +320,859	+70%	+$3.42M	0.03%	85
2020 Q3	$5.37M	Sell	461,324 -24,300	-5%	-$352K	0.02%	79
2020 Q2	$7.79M	Buy	485,624 +328,851	+210%	+$3.65M	0.03%	70
2020 Q1	$939K	Hold	156,773	–	–	0.01%	101
2019 Q4	$2.07M	Hold	156,773	–	–	0.01%	84
2019 Q3	$1.95M	Hold	156,773	–	–	0.01%	86
2019 Q2	$2.52M	Hold	156,773	–	–	0.02%	78
2019 Q1	$4.93M	Hold	156,773	–	–	0.03%	61
2018 Q4	$5.15M	Sell	156,773 -78,521	-33%	-$2.58M	0.04%	56
2018 Q3	$7.22M	Hold	235,294	–	–	0.05%	61
2018 Q2	$6.3M	Buy	+235,294	New	+$6.22M	0.05%	65

Other funds holding AUTL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baker Bros. Advisors's AUTL Position: Q2 2021 in Review

Baker Bros. Advisors sold out of Autolus Therapeutics (AUTL) in Q2 2021, closing a stake of 461,726 shares — an estimated $2.65M sold.

Baker Bros. Advisors first reported a position in AUTL in Q2 2018 and held it in 12 quarters. The position peaked at $7.79M in Q2 2020. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2021.

Baker Bros. Advisors reported no remaining Autolus Therapeutics position as of Q2 2021 after selling out during the quarter.
Baker Bros. Advisors sold 461,726 Autolus Therapeutics shares in Q2 2021, an estimated $2.65M.
Baker Bros. Advisors first reported a position in Autolus Therapeutics in Q2 2018 and held it in 12 quarters.
Baker Bros. Advisors's Autolus Therapeutics position peaked at $7.79M in Q2 2020.
69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2021.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.